The UK Nuclear Medicine Equipment Market was valued at $268 Million in 2025 and projected to reach to $346 Million by 2030, representing a compound annual growth rate of 5.2%. The UK nuclear medicine equipment market is positioned for steady growth, supported by NHS modernisation initiatives and increasing clinical demand for advanced diagnostic imaging.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The UK National Health Service continues to allocate significant capital expenditure towards modernising diagnostic imaging departments, driving demand for advanced nuclear medicine equipment across NHS trusts and private healthcare facilities.
UK hospitals are increasingly adopting PET-CT and SPECT-CT hybrid systems, which combine anatomical and functional imaging capabilities, improving diagnostic accuracy and patient outcomes in oncology, cardiology, and neurology applications.
The UK's ageing population is driving higher prevalence of chronic diseases including cancer, cardiovascular conditions, and neurological disorders, necessitating increased nuclear medicine diagnostic procedures and equipment demand.
The UK maintains stringent regulatory frameworks through the Care Quality Commission and MHRA, ensuring high standards for nuclear medicine equipment, which supports market confidence and drives investment in quality diagnostic solutions.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | DIAGNOSTIC IMAGING CENTERS (End User) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 4.62% from 2025 to 2030 |
| Largest Segment | IMAGING MODALITIES (System Type) |
| Market Size Base Year (Billions) | ~USD 6.63 (2025) |
| Revenue Forecast (Billions) | ~USD 8.31 (2030) |
| Segments Covered | System Type, Type, Therapeutic Area, Dimension, End User, Type 2023–2030 |
6 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CANCER TREATMENT CENTERS | 35.1 | 37.1 | 39.2 | 41.4 | 43.8 | 46.2 | 48.8 | 51.4 | 5.6 |
| DIAGNOSTIC IMAGING CENTERS | 49.7 | 52.7 | 55.8 | 59.1 | 62.6 | 66.3 | 70.2 | 74.2 | 5.9 |
| HOSPITALS | 133.8 | 140.8 | 148 | 155.6 | 163.4 | 171.7 | 180.3 | 189.2 | 5 |
| OTHER END USERS | 22.7 | 23.8 | 24.9 | 26.1 | 27.3 | 28.5 | 29.8 | 31.1 | 4.5 |
| TOTAL | 241.3 | 254.4 | 268 | 282.2 | 297.1 | 312.7 | 329 | 346 | 5.2 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PHILIPS | Netherlands | Public Company | Imaging Systems (PET, SPECT, Gamma),Software (Image Management, PACS, Treatment, Analytics, Workflow),Detectors & Counters (GM Counter, Dose Calibrator and Related), |
| DIGIRAD CORPORATION | United States | Private Company | Imaging – SPECT / Gamma cameras,Imaging – PET,Radiation detection (GM counters, dose calibrators), |
| TOSHIBA CORPORATION | Japan | Private Company | Imaging Equipment (PET, SPECT, Gamma),Radiation Measurement (GM Counter, Dose Calibrator),Software (Image Management, PACS, Treatment, Analytic, Workflow), |
| SIEMENS AG | Germany | Public Company | Imaging Systems (PET, SPECT, Gamma Cameras),Software (Image Management, PACS, Treatment, Analytics, Workflow),Therapy-adjacent Solutions (Onco, Cardio, Neuro, Ortho Planning/Support), |
| GE HEALTHCARE | United States | Public Company | Imaging – PET,Imaging – SPECT,Imaging – Gamma cameras, |
| SIEMENS HEALTHINEERS AG | Germany | ||
| KONINKLIJKE PHILIPS N.V. | Netherlands | Public Company | Imaging Systems (PET, SPECT, Gamma Cameras),Software (Image Management, PACS, Analytics, Workflow, Treatment Planning Interfaces),Therapy-related Applications (Oncology, Cardiology, Neurology, Orthopedic Planning), |
| MIRION TECHNOLOGIES, INC. | United States | Public Company | Imaging-related equipment (PET/SPECT/Gamma-adjacent QA, detectors, cameras),Radiation measurement & counters (GM counters, dose calibrators, health-physics),Software (image/spectroscopy analysis, QA, workflow, treatment support), |
| DOSISOFT SA | France | Private Company | Imaging-related software (PET/SPECT/Gamma image management & PACS integration),Treatment planning & dosimetry software (Onco/Cardio/Neuro/Ortho),Analytics & workflow orchestration, |
| SEGAMI CORPORATION | Japan | Private Company | Imaging Equipment (PET/SPECT/Gamma),GM Counters & Dose Calibrators,Nuclear Medicine Software (Image Management, PACS, Treatment, Analytic, Workflow), |
| LABLOGIC SYSTEMS LTD. | United Kingdom | Private Company | Imaging-adjacent QC hardware (gamma counters, dose calibrator-related QC, radiochromatography hardware),CDS / Image & data management software for radiopharmaceutical workflows,LIMS / workflow and analytic software for nuclear medicine and radiochemistry labs, |
Philips is a Dutch multinational public company founded in 1891 with 63,670 employees. The company operates across healthcare, consumer lifestyle, and lighting sectors.
Digirad Corporation is a United States-based private company founded in 1985 with 194 employees.
Toshiba Corporation is a Japanese private company founded in 1875 with 106,648 employees, operating across multiple industrial and technology sectors.
Siemens AG is a German public company founded in 1847 with 310,312 employees, operating across industrial, infrastructure, and healthcare sectors.
GE Healthcare is a United States-based public company founded in 2022 with 54,000 employees.
Siemens Healthineers AG is a German healthcare company within the Siemens group.
Koninklijke Philips N.V. is a Dutch multinational public company founded in 1891 with 63,670 employees, operating across healthcare, consumer lifestyle, and lighting sectors.
Mirion Technologies, Inc. is a United States-based public company founded in 2005 with 3,281 employees.
Dosisoft SA is a French private company founded in 2002.
Segami Corporation is a Japanese private company with 1,501 employees.
Lablogic Systems Ltd. is a United Kingdom-based private company founded in 1980.
The UK nuclear medicine equipment market is valued at $268.0 million in 2025.
The UK nuclear medicine equipment market is projected to reach $346.0 million by 2030.
The UK nuclear medicine equipment market is growing at a compound annual growth rate (CAGR) of 5.2% from 2025 to 2030.
Key drivers include the UK's aging population, rising prevalence of chronic diseases, NHS investment in diagnostic imaging, adoption of hybrid imaging technologies, and regulatory support from the MHRA.
PET-CT and SPECT-CT hybrid imaging systems are among the most in-demand technologies in the UK market, driven by their clinical efficacy and integration into NHS imaging protocols.
This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the nuclear medicine equipment market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the nuclear medicine equipment market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the World Health Organization (WHO), the Organisation for Economic Co-operation and Development (OECD), Healthcare Information and Management Systems Society (HIMSS), Centers for Disease Control and Prevention (CDC), ClinicalTrials.gov, Expert Interviews, and MarketsandMarkets Analysis.
Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the nuclear medicine equipment market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends, to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources are mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.
Primary research was conducted to identify segmentation types, industry trends, key players, and key market dynamics such as drivers, restraints, opportunities, challenges, and strategies adopted by key players.
After completing the market engineering process, which includes calculations for market statistics, market breakdown, size estimations, forecasting, and data triangulation, extensive primary research was conducted. This research aimed to gather information and verify the critical numbers obtained during the market analysis. Additionally, primary research was conducted to identify different types of market segmentation, analyze industry trends, evaluate the competitive landscape of nuclear medicine equipment offered by various players, and understand key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies employed by key market participants.
In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
Breakdown of Primary Interviews
Note 1: Other designations include sales, marketing, and product managers.
Note 2: Tiers are defined based on a company’s total revenue, as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and top-down approach (assessment of utilization/adoption/penetration trends, by product type, therapeutic area, dimension, end user, and region).

After arriving at the overall market size, from the market size estimation process explained above, the nuclear medicine equipment market was split into segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the nuclear medicine equipment market.
Nuclear medicine equipment refers to specialized medical devices used to perform diagnostic and therapeutic procedures involving radioactive substances. These include imaging systems such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) scanners, as well as gamma cameras and hybrid imaging systems. The equipment enables the detection, imaging, and tracking of radiopharmaceuticals within the body, playing a crucial role in disease diagnosis, monitoring, and targeted radionuclide therapy.
Full forecast, segment splits, and company analysis for all Nuclear Medicine Equipment Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report